801 results about "Antiinflammatory drug" patented technology

An oral solid dosage form includes a therapeutically effective amount of an NSAID and a proton pump inhibitor in an amount effective to inhibit or prevent gastrointestinal side effects normally associated with the NSAID. Also disclosed is a method of treating a human patient in need of antiinflammatory, analgesic and/or antipyretic therapy, comprising orally administering to the patient an oral pharmaceutical dosage form which includes a therapeutically effective amount of an NSAID and an amount of a proton pump inhibitor effective to substantially inhibit gastrointestinal side effects of the NSAID. The invention is further related to a method of prophylactically treating a human patient who is on a therapy known to have significant gastrointestinal side effects or is about to begin such a therapy, via concurrent administration of an NSAID and a proton pump inhibitor in a combination (single) oral dosage form.

Disclosed is a pharmaceutical dosage form including a therapeutically effective amount of an NSAID and an antiulcerative agent.

Topical alcoholic or aqueous alcoholic gels containing ibuprofen or other NSAIDs, such as, naproxen, in substantially neutral salt form, have enhanced penetration through skin and may provide rapid pain/inflammation relief by including in the formulation 2-n-nonyl-1,3-dioxolane or other hydrocarbyl derivative of 1,3-dioxolane-or 1,3-dioxane or acetal, as skin penetration enhancing compound. The amount of propylene glycol may be varied to adjust the initial flux of the NSAID through the skin, especially for ibuprofen, naproxen, and ketorolac.

The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.

A method of treating animals having cancer by administration of secondary amide derivatives of various COOH-containing drugs, such as COOH-containing NSAIDs, for instance, indomethacin.

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma.

The invention particularly relates to those drug combinations which, in addition to one or more, preferably one PDE4 inhibitor of general formula 1

wherein X is SO or SO₂, but preferably SO, and wherein

R³ denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl and wherein R¹ and R² have the meanings given in claim 1,

contain at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

The invention discloses acid-sensitive controlled-release anti-inflammatory gel. The gel is formed by phenylboronic acid modified hyaluronic acid and tannic acid under the neutral to slightly alkalinecondition, and tannic acid can be released under the acidic condition. Amiloride and analogues or non-steroidal anti-inflammatory drugs thereof can be added to the anti-inflammatory gel. The invention also discloses a preparation method of the acid-sensitive controlled-release anti-inflammatory gel. The method comprises two steps including preparation of phenylboronic acid modified hyaluronic acid and preparation of the acid-sensitive controlled-release anti-inflammatory gel. The invention also discloses an application of the acid-sensitive controlled-release anti-inflammatory gel in preparation of drugs for treating physiological and pathologic change related diseases caused by decrease of pH value due to gathering of inflammatory metabolites. The gel has the lubricating function of hyaluronic acid, can relieve the stress of joints and promote backflow and update of metabolism, also has the non-specific anti-inflammatory, antioxidation, anti-effusion and analgesia functions of tannicacid, can inhibit excessive inflammatory response and body hypermetabolic reaction and is a new controlled-release anti-inflammatory gel.

The invention provides an oleanolic acid triterpenoid, whose A ring and C ring contain multiple oxygen substituents, represented as formula (1). The inventive compound can inhibit the growth activity of tumor cell, thereby being applied in the preparation of anti-tumor drug and can inhibit mice ear swelling caused by dimethylbenzene, thereby being applied in the preparation of anti-inflammatory agent. The formula (1) is represented as above.

The invention describes novel organic nitric oxide enhancing salts of nonsteroidal antiinflammatory drugs (NSAIDs) and novel compositions comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating inflammation, pain and fever; (b) treating gastrointestinal disorders; (c) facilitating wound healing; (d) treating gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; (e) treating inflammatory disease states and/or disorders; (f) treating ophthalmic disorders; (h) treating peripheral vascular diseases; (i) treating diseases resulting from oxidative stress; (j) treating endothelial dysfunctions; and (k) treating diseases caused by endothelial dysfunctions. The organic nitric oxide enhancing compounds that form salts with the NSAIDs are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.

The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

The present invention provides methods for treating a variety of hyperproliferative and inflammatory mucocutaneous disorders, including, basal cell carcinoma, squamous cell carcinoma, psoriasis and atopic dermatitis, as well as skin irritation and disorders associated with skin aging and skin photodamage using inhibitors of cholesterol metabolism. The present invention further relates to the discovery that the combined use of several inhibitors of cholesterol metabolism produces synergistic effects. Furthermore, the present invention is directed to the use of inhibitors of cholesterol metabolism as excipients to enhance the effects of antiinflammatory drugs.

The invention discloses a solid phase microextraction coating of a hydroxyl cucurbituril as well as a preparation method and an application thereof, relates to an analyzing sample pre-treatment technology, and belongs to the technical field of analytical chemistry. The solid phase microextraction coating is characterized in that a common pentabasic cucurbituril or six-membered cucurbituril is subjected to potassium peroxodisulfate oxidation and cation exchange resin separation and purification so as to obtain the hydroxyl cucurbituril through, the hydroxyl cucurbituril is bonded on a sol-gel mesh through a chemical reaction so as to obtain the solid phase microextraction coating, the coating is utilized to prepare a solid phase microextraction fibre which is combined with a gas chromatography, the environmental water sample containing polycyclic aromatic hydrocarbon is analysed, and the coating is utilized to prepare a solid phase microextraction stirring rod which is combined with a high performance liquid chromatography so as to analyze non-steroid antiinflammatory drugs. The solid phase microextraction coating provided by the invention has the advantages that the superficial area of the coating is large, and the extraction capacity is large; and the solid phase microextraction coating is a novel solid phase microextraction coating, is used for analyzing, high in selectivity, low in detection limitation, wide in linearity range, and good in selectivity.

The invention belongs to the field of pharmaceutical preparations and provides a Celecoxib nanosuspension and a preparation method thereof. Celecoxib is a novel non-steroidal anti-inflammatory drug, inhibits cyclooxygenase -2(COX-2) is through specificity, has anti-inflammatory and pain-easing effects and is clinically used for treating osteoarthritis and rheumatoid arthritis. However, the Celecoxib has very low solubility and in-vivo bioavailability. In order to increase the dissolution and the bioavailability of the drug, a high-speed shearing combined high-pressure homogenizing method is adopted to prepare the Celecoxib nanosuspension, the particle size and the polydispersion index PI are used as indicators for formulation technology optimization, a laser particle analyzer and a transmission electron microscope are adopted to study the particle size and form of the drug, the dissolution of the drug is evaluated through in-vitro dissolution experiments, and rat in-vivo pharmacokinetic study is conducted. Measurement results prove that the drug particle size of the nanosuspension is 50-500 nm, and the dissolution and the in-vivo bioavailability of the drug are increased obviously.

This invention relates to the use of nicotine receptor agonists or analogues or derivatives thereof for treating inflammatory pulmonary diseases. Such agonists have fewer side effects than other anti-inflammatory drugs, such as steroids. Moreover, these agonists can be used alone or in combination with other anti-inflammatory drugs to alleviate pulmonary diseases.

The invention relates to application of 10-O-(dimethylaminoethyl) Ginkgolide B in preparing antipyretic, analgesic and anti-inflammatory medicaments. Indicated by tests, the 10-O-(dimethylaminoethyl) Ginkgolide B can inhibit cyclooxygenase-2, has obvious effects of dissociating heat, easing pain and resisting various acute and chronic inflammations and has the advantages of less side effect and low toxicity.

The invention provides a biodegradable cardia support. The biodegradable cardia support comprises a biodegradable support framework which is formed by weave of biodegradable high polymer material filaments, and a layer of controlled-release drug layer is coated on the surface of the biodegradable support framework. The support framework and drug carriers are made of high polymer biodegradable materials and can fully and automatically degradate after time window treatment is finished, and therefore the trouble of taking out the support is avoided. In addition, the controlled-release drug layer can release anti-inflammatory drugs stably through drug controlled-release technology, and therefore fibroblast hyperplasia caused by esophagus repair reaction can be effectively restrained, subsequent scar tissue hyperplasia and thickening can be reduced, and tissue hyperplasia on the surface of the support after the support is implanted is restrained. Thus, the time window of support implantation treatment can be prolonged, supporting force of the support on tube walls can be increased, and long-dated reappearance can be reduced.

The invention discloses a multifunctional microemlusion gel preparation and a preparation process thereof, and belongs to the technical field of medicines. The preparation mainly comprises bulk pharmaceutical chemicals (such as non-steroidal anti-inflammatory drugs-diclofenac sodium, ibuprofen, indometacin, antifungal drugs-ornidazole, antiviral drugs-ganciclovir, hormone drugs-dexamethasone, local anesthesia drugs-lidocaine and irritants-menthol), a cationic polymer and a microemlusion, can further comprise gel or a thickener, and can be used for transdermal drug delivery and local drug delivery. The preparation process is simple, convenient, good in stability and pollution-free. Compared with existing cream and gel, the preparation has the advantages that a novel action mechanism is adopted, the accumulative penetration amount of unit area of drugs is remarkably increased, a certain slow-release effect is achieved, and the drug delivery frequency and the drug delivery amount can be reduced; a chemical penetration enhancer and a conventional preservative are not added, a certain bacterial inhibition effect is achieved, the skin irritation is avoided, and the use safety of the drugs is improved.